CD209 and neoplasm: Canine DC-SIGN-targeted Ad5 vectors were developed in order to evaluate and compare the effectiveness of CD40- and DC-SIGN-targeted Ad5 vaccines against canine melanoma, a spontaneous and aggressive tumor which provides a stringent study system for the evaluation of antitumor immunotherapies [133].